Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

The provider of oil production-enhancement services saw its share price jump about 24% in its first day of trading.

According to a 2019 market research report by Wamda ... the company’s enterprise value at IPO would approximate $1.1 billion, excluding the effects of underwriter over-allotment options.

A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.

To judge by the comments from Term Sheet readers who particpated in our survey, the coming year may bring some relief as a new presidential administration and regulatory regime come into effect ...

(Reuters) - Smithfield Foods is targeting a valuation of up to $10.73 billion in its U.S. initial public offering, the ...

climbing interest rates and Russia’s invasion of Ukraine helped cast a chilling effect on new issues. Justworks, which was chasing a $2 billion valuation, decided to keep its IPO registration ...